Johnson & Johnson is focusing on expanding its pharmaceutical and medical technology portfolio following the spin-off of its consumer health arm, investing over $60 billion in research and development and acquisitions. CEO Joaquin Duato highlights the intention to target unmet needs in high-growth markets. Meanwhile, the company is dealing with numerous lawsuits related to its talc products and is aiming to resolve them through bankruptcy proceedings for Red River Talc LLC, which could lead to significant settlements for claimants.
Johnson & Johnson has invested over $60 billion in R&D and acquisitions post-split to enhance their focus on pharmaceuticals and innovation in healthcare.
The company is currently aiming to address unmet needs in high-growth markets while managing significant legal challenges from past talc product claims.
CEO Joaquin Duato emphasized that investment levels are strategically designed to shift the portfolio towards more innovative sectors in pharmaceuticals.
A spokesperson stated that upcoming hearings for Red River Talc LLC are expected to advance one of the largest mass tort settlements, improving outcomes for claimants.
Collection
[
|
...
]